Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

New strategies in pleural mesothelioma: BAP1 and NF2 as novel targets for therapeutic development and risk assessment.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Sept 2012

Ladanyi Marc, Zauderer Marjorie G, Krug Lee M, Ito Tatsuo, McMillan Robert, Bott Matthew, Giancotti Filippo

Abstract excerpt

Malignant pleural mesothelioma (MPM) is a highly lethal cancer with limited therapeutic options. Recent work has focused on the frequent somatic inactivation of two tumor suppressor genes in MPM-NF2 (Neurofibromatosis type 2) and the recently identified BAP1 (BRCA associated protein 1). In addition, germline mutations in BAP1 have been identified that define a new familial cancer syndrome, which includes MPM,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genetic Predisposition to Disease
Share to Germ-Line Mutation

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Mesothelioma

Share to Molecular Targeted Therapy

Share to Neurofibromatosis 2

Share to Risk Assessment

Share to Tumor Suppressor Proteins

Share to Ubiquitin Thiolesterase

Source

Open in PubMed Open full text

Identifiers

PMID: 22825583
DOI: 10.1158/1078-0432.CCR-11-2375
PMCID: PMC3432735

Genes

BAP1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

New strategies in pleural mesothelioma: BAP1 and NF2 as novel targets for therapeutic development and risk assessment.PMID 22825583Read ↗

BAP1, a tumor suppressor gene driving malignant mesotheliomaSemantic proximity Read ↗

Meningiomas in Patients With Malignant Pleural Mesothelioma Harboring Germline BAP1 Mutations.Semantic proximity Read ↗

BAP1 Mutations and Pleural Mesothelioma: Genetic Insights, Clinical Implications, and Therapeutic PerspectivesSemantic proximity Read ↗

BAP1 protein is a progression factor in malignant pleural mesothelioma.Semantic proximity Read ↗

The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma.Semantic proximity Read ↗

Combined deletion of Bap1, Nf2, and Cdkn2ab causes rapid onset of malignant mesothelioma in miceSemantic proximity Read ↗

Isolated BAP1 Genomic Alteration in Malignant Pleural Mesothelioma Predicts Distinct Immunogenicity with Implications for Immunotherapeutic ResponseSemantic proximity Read ↗

Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma.Semantic proximity Read ↗

Isolated <i>BAP1</i> loss in malignant pleural mesothelioma predicts immunogenicity with implications for immunotherapeutic responseSemantic proximity Read ↗

Molecular pathogenesis of malignant mesotheliomaSemantic proximity Read ↗

BAP1 mutation is a frequent somatic event in peritoneal malignant mesothelioma.Semantic proximity Read ↗

Clinical Characteristics of Patients with Malignant Pleural Mesothelioma Harboring Somatic BAP1 MutationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.